# R1 Clinical-Safety Review — mixed_phenotype_acute_leukaemia (MPAL)

VERDICT: APPROVE

## 1. Safety
No unsafe, misleading, or harmful absolute statements. Every therapeutic
directive is hedged appropriately: ALL-based induction for non-BCR-ABL1/
non-KMT2A MPAL is stated as "most commonly" with an explicit myeloid-predominant
exception; transplant is "considered for many," not mandated; treatment is
routed to acute-leukaemia experts and trials. No statement would cause harm if a
clinician followed it. No definitive claim oversteps decision-support.

## 2. Grounding
Consistent with DeVita 12th ed. + NCCN standard of care. No fabricated or
outdated regimen. Key claims are clinically correct and uncontroversial:
- BCR-ABL1+ MPAL → ALL-type induction backbone + BCR-ABL1-targeted TKI (mirrors
  Ph+ ALL). Correct, NCCN-consistent.
- KMT2A/MLL-rearranged → higher-risk, lower threshold to transplant. Correct.
- Non-BCR-ABL1/non-KMT2A → ALL-directed induction preferred, per retrospective
  outcome data, myeloid-directed considered when myeloid antigens predominate.
  Correct and appropriately hedged.
- Allo-HSCT in CR1, no role for surgery, RT limited to supportive/palliative,
  MRD + BCR-ABL1 transcript monitoring. All correct.

Crucially, the draft does NOT mis-attribute any of these to DeVita: it flags that
DeVita names MPAL only in passing with no dedicated management section, and tags
essentially every specific claim "(general oncology standard, not from DeVita's
section on this disease)." The only claims stated as DeVita-grounded (diagnostic
framework via morphology/immunophenotyping/cytogenetics; recognition of
ambiguous-lineage disease with "clinical and therapeutic implications") are
faithfully in DeVita. No "cite DeVita for a claim not in DeVita" violation.

## 3. Dose-free
Confirmed. No mg, mg/m2, AUC, mg/kg, day-N/cycle-N schedules, or named agents.
Only drug/regimen classes ("ALL-type induction backbone", "BCR-ABL1-targeted
tyrosine kinase inhibitor"). Independent adversarial grep also found zero dose
hits.

## 4. Scope
Appropriately hedged as decision-support, not a directive. Emphasises expert
centre review, individualised strategy, prompt referral, and trial enrolment.

## 5. Adversarial flags
The .verdict.md verdict was CLEAN (ready for R1). Its single carried-forward flag
is NOT a mis-source or scope-creep finding: it notes the treatment-approach
section rests on general-oncology-standard knowledge (because DeVita has no MPAL
management section) rather than a citable primary text in the job corpus, and
asks R1 to confirm the BCR-ABL1-TKI / KMT2A-transplant / ALL-preferred-induction
claims against NCCN directly. Those three claims are clinically uncontroversial
and NCCN-consistent (confirmed above), AND they are already correctly relabelled
in the sidecar as general oncology standard, not DeVita-sourced. This is exactly
the condition under which APPROVE is permitted: no claim is falsely attributed to
DeVita, and the flagged items are uncontroversial standard-of-care.

Goldens changed: no (documentation/KB narrative only; no engine/rule change).
